文献速递肿瘤 PET/CT

18F-BMS-986229 PET评估胃食管癌程序性死亡配体1状态

18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer.
PubMed 文献 · J Nucl Med · 2024-05-01

这项前瞻性先导研究在10例胃食管腺癌患者中评估了靶向PD-L1的放射性示踪剂18F-BMS-986229 PET的安全性、可行性及与病理评估的一致性;未发生示踪剂相关不良事件,影像与病理评估在88%的活检病灶中一致,但小样本量使生存分析无法得出确定性结论。

要点

  • 18F-BMS-986229 PET在胃食管腺癌中安全可行,未发生示踪剂相关不良事件。
  • 影像评估与病理PD-L1评估在88%的活检病灶中一致,摄取值与联合阳性评分相关系数为0.64。
  • 71%有示踪剂摄取的患者同时存在无摄取病灶,提示PD-L1表达存在患者内异质性。

核心结论

  • PD-L1 PET显像安全、可行,与病理评估一致,提供了一种潜在的无创评估PD-L1表达的工具。

研究设计与样本

  • 前瞻性先导研究,纳入10例胃食管腺癌患者,静脉注射18F-BMS-986229 370 MBq后60分钟行全身PET/CT,主要终点为安全性和可行性。
  • 试验注册号为NCT04161781,研究时间为2020年2月3日至2022年2月2日。

主要发现

  • 未发生与18F-BMS-986229示踪剂相关的不良事件,显像未导致治疗延迟,主要终点达成。
  • 影像评估PD-L1表达与病理评估在88%的活检病灶中一致。
  • 18F-BMS-986229 PET摄取值与病理联合阳性评分相关,Spearman秩相关系数为0.64。
  • 71%有18F-BMS-986229摄取的患者同时存在无示踪剂摄取的病灶,突显PD-L1表达的患者内异质性。
  • 接受一线PD-1抑制剂治疗且有任一病灶示踪剂摄取的患者,中位无进展生存期为28.4个月,无任一病灶摄取者为9.9个月,但小样本量使任何确定性结论无法成立。

局限性

  • 小样本量使任何确定性结论无法成立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed death ligand 1 (PD-L1) expression, pathologic assessments of PD-L1 status have several limitations. Single-site biopsies do not adequately capture disease heterogeneity within individual tumor lesions or among several lesions within the same patient, the PD-L1 combined positive score is a dynamic biomarker subject to evolution throughout a patient's disease course, and repeated biopsies are invasive and not always feasible. Methods: This was a prospective pilot study of the PD-L1-targeting radiotracer, 18F-BMS-986229, with PET imaging (PD-L1 PET) in patients with gastroesophageal cancer. Patients were administered the 18F-BMS-986229 radiotracer intravenously at a dose of 370 MBq over 1-2 min and underwent whole-body PET/CT imaging 60 min later. The primary objective of this study was to evaluate the safety and feasibility of 18F-BMS-986229. The trial is registered with ClinicalTrials.gov (NCT04161781). Results: Between February 3, 2020, and February 2, 2022, 10 patients with gastroesophageal adenocarcinoma underwent PD-L1 PET. There were no adverse events associated with the 18F-BMS-986229 tracer, and imaging did not result in treatment delays; the primary endpoint was achieved. Radiographic evaluation of PD-L1 expression was concordant with pathologic assessment in 88% of biopsied lesions, and 18F-BMS-986229 uptake on PET imaging correlated with pathologic evaluation by the combined positive score (Spearman rank correlation coefficient, 0.64). Seventy-one percent of patients with 18F-BMS-986229 accumulation on PET imaging also had lesions without 18F-BMS-986229 uptake, highlighting the intrapatient heterogeneity of PD-L1 expression. Patients treated with frontline programmed death 1 inhibitors who had 18F-BMS-986229 accumulation in any lesions on PET imaging had longer progression-free survival than patients without tracer accumulation in any lesions (median progression-free survival, 28.4 vs. 9.9 mo), though the small sample size prevents any definitive conclusions. Conclusion: PD-L1 PET imaging was safe, feasible, and concordant with pathologic evaluation and offers a potential noninvasive tool to assess PD-L1 expression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cytryn SL, Pandit-Taskar N, Lumish MA, et al. 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. J Nucl Med. 2024. PMID: 38514081. doi:10.2967/jnumed.123.267186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。